Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 80 citing articles:

Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population
Jonathan J. Lau, Samuel M. S. Cheng, Kathy Leung, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 348-357
Open Access | Times Cited: 145
Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study
Ramandip Grewal, Sophie A. Kitchen, Lena Nguyen, et al.
BMJ (2022), pp. e071502-e071502
Open Access | Times Cited: 141
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
Patricia L. Winokur, Juleen Gayed, David Fitz-Patrick, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 3, pp. 214-227
Open Access | Times Cited: 105
Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: A nationwide, retrospective cohort study in Sweden
Peter Nordström, Marcel Ballin, Anna Nordström
The Lancet Regional Health - Europe (2022) Vol. 21, pp. 100466-100466
Open Access | Times Cited: 66
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, et al.
BMJ (2023), pp. e075286-e075286
Open Access | Times Cited: 64
COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities
Kevin Bardosh, Allison Krug, Euzebiusz Jamrozik, et al.
Journal of Medical Ethics (2022) Vol. 50, Iss. 2, pp. 126-138
Open Access | Times Cited: 45
Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Ramandip Grewal, Lena Nguyen, Sarah A. Buchan, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 37
Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countries
Niklas Andersson, Emilia Myrup Thiesson, Ulrike Baum, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 31
Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine
Lorenzo Azzi, Daniela Dalla Gasperina, Giovanni Veronesi, et al.
EBioMedicine (2023) Vol. 88, pp. 104435-104435
Open Access | Times Cited: 28
Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster
Julien Favresse, Constant Gillot, Jean‐Louis Bayart, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 34
Hospitalized Patients With Severe Coronavirus Disease 2019 During the Omicron Wave in Israel: Benefits of a Fourth Vaccine Dose
Tal Brosh‐Nissimov, Khetam Hussein, Yonit Wiener‐Well, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e234-e239
Open Access | Times Cited: 28
Does natural and hybrid immunity obviate the need for frequent vaccine boosters against SARS‐CoV‐2 in the endemic phase?
Stefan Pilz, John P. A. Ioannidis
European Journal of Clinical Investigation (2022) Vol. 53, Iss. 2
Open Access | Times Cited: 28
Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation
Sivan Gazit, Yaki Saciuk, Galit Perez, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 7, pp. e495-e505
Open Access | Times Cited: 17
Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai
Qianhui Wu, Hongyu Wang, Jianpeng Cai, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 15
Effectiveness of a fourth SARS‐CoV‐2 vaccine dose in previously infected individuals from Austria
Alena Chalupka, Lukas Richter, Ali Chakeri, et al.
European Journal of Clinical Investigation (2023) Vol. 54, Iss. 3
Open Access | Times Cited: 15
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques
Christopher T Edwards, Kirti A. Karunakaran, Elijah Garcia, et al.
PLoS Pathogens (2025) Vol. 21, Iss. 1, pp. e1012456-e1012456
Open Access
The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose
Nadia Mazarakis, Zheng Quan Toh, Eleanor Neal, et al.
Journal of Infection (2025), pp. 106447-106447
Open Access
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
Ioannis Ntanasis‐Stathopoulos, Vangelis Karalis, Maria Gavriatopoulou, et al.
HemaSphere (2022) Vol. 6, Iss. 8, pp. e764-e764
Open Access | Times Cited: 25
Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
Matan Yechezkel, Merav Mofaz, Amichai Painsky, et al.
The Lancet Respiratory Medicine (2022) Vol. 11, Iss. 2, pp. 139-150
Open Access | Times Cited: 25
Assessing acceptability of the fourth dose against COVID-19 among Chinese adults: A population-based survey
Chenyuan Qin, Min Du, Yaping Wang, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 14
Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis
Obaidur Rahman, Taro Kamigaki, Moe Moe Thandar, et al.
BMJ Open (2023) Vol. 13, Iss. 12, pp. e076892-e076892
Open Access | Times Cited: 14
Hesitancy to Receive the Second COVID-19 Vaccine Booster Dose among Older Adults in Hong Kong: A Random Telephone Survey
Paul Chan, Marco Lok-tin Lee, Yuan Fang, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 392-392
Open Access | Times Cited: 12
Increased vaccine sensitivity of an emerging SARS-CoV-2 variant
Joseph A. Lewnard, Vennis Hong, Jeniffer S. Kim, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Safety, immunogenicity and protective effectiveness of heterologous boost with a recombinant COVID-19 vaccine (Sf9 cells) in adult recipients of inactivated vaccines
Wenxin Luo, Jiadi Gan, Zhu Luo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 4
Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System
Aisling R. Caffrey, Haley J. Appaneal, Vrishali V. Lopes, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top